Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma (INZY – Research Report) today and set a price target of $23.00. The company’s shares opened today at $3.41.
Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Lexicon Pharmaceuticals. According to TipRanks, Stringer has an average return of 5.3% and a 46.63% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inozyme Pharma with a $22.00 average price target, representing a 545.16% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.
See today’s best-performing stocks on TipRanks >>
INZY market cap is currently $139.5M and has a P/E ratio of -1.32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Read More on INZY:
- H.C. Wainwright Remains a Buy on Tempest Therapeutics (TPST)
- Richardson Electronics Participating in 2022 KIEES Summer Academic Conference in South Korea
- Security National Financial Corporation Reports Financial Results for the Quarter Ended June 30, 2022
- Here’s Why Revolve Stock was Down Monday Morning
- LNK’s Awakening: Cybercriminals Moving from Macros to Shortcut Files to Access Business PCs
